TLC BioSciences

Long history in liposomal science

About Us

Intro

History & Awards

Founded in 1997 by renowned liposome scientist Dr. Keelung Hong, TLC BioSciences is advancing innovative lipid-based drug delivery technologies. As a researcher, Dr. Hong worked alongside Dr. Demetrios Papahadjopoulos, the pioneering father of liposome research, and was heavily involved in the development of the first FDA-approved liposomal drugs, Doxil and Onivyde. After co-founding his own liposomal company in the United States, and driven by his vision to bring liposome expertise to his homeland of Taiwan, Dr. Hong established TLC.

Powered by our proprietary LipAD® platforms, we have successfully developed 3 approved liposomal drugs for oncology indications that have been outlicensed for commercialization. Recently, we have strategically shifted focus to address unmet medical needs in orthopedics and pain management. We have built a strong pipeline with late clinical stage liposome solutions for osteoarthritis and postsurgical pain management, along with cutting-edge lipid nanoparticle candidates for cartilage protection and regeneration. With imminent commercial launches in next couple of years and support from a seasoned leadership team, TLC is realizing our founding mission - delivering transformative lipid nanomedicines rooted in Taiwan to improve patient outcomes worldwide.

History & Awards

With our rich history and professional expertise, we have garnered numerous domestic and international awards and recognition, showcasing the exceptional quality and value of our brand.

2023

TLC599 Phase 3 data shows clinical benefit to 24 weeks; second injection furthered benefits to 52 weeks

2022

Entered $670M agreement with Endo

2021

CDSCO of India approved the New Drug Application (NDA) of Ampholipad
Ampholipad marketed and sold in India
Ranked top 5% of all publicly listed companies in annual corporate governance evaluations
Voluntarily delisted from TPEx and Nasdaq

2020

Taiwan FDA approved Scale-up & Post-approval Changes application for Ampholipad®
TLC19 receives Australian and Taiwan approval to initiate Phase I clinical trial
Ranked top 5% of all publicly listed companies in annual corporate governance evaluations

2019

Phase 3 clinical trial for TLC599 in the US and Australia
Phase 2 clinical trial for TLC590 in bunionectomy in the US
European Medicine Agency grants Orphan Drug Designation to TLC178 for the treatment of soft tissue sarcoma.
Ranked top 5% of all publicly listed companies in annual corporate governance evaluations

2018

Received clearance to conduct clinical trials for TLC590 from US FDA
Phase 1/2 clinical trial for TLC590 in hernia repair surgery
TLC178 received IND clearance from US FDA for pediatric Phase I/II clinical trial in rhabdomyosarcoma
Ranked top 5% of all publicly listed companies in annual corporate governance evaluations
Dual-listed on Nasdaq Marketplace (ticker: TLC)

2017

Phase 2 clinical trial for TLC599
TLC178 designated by US FDA as drug for Rare Pediatric Disease in the treatment of rhabdomyosarcoma
TLC178 received Orphan Drug Designation by US FDA for the treatment of soft tissue sarcoma
Ranked top 5% of all publicly listed companies in annual corporate governance evaluations

2016

Phase 1/2 clinical trial for TLC599
TLC178, new dosage form of NanoVNB, received clearance for clinical trials in Taiwan and the US
TLC178 granted orphan drug designation in the US for the treatment of cutaneous T-cell lymphoma (CTCL)
Ranked top 5% of all publicly listed companies in annual corporate governance evaluations

2015

Established subsidiary in Tokyo
Received the highest rating of A++ in the annual Publicly Traded Company Information Evaluation
Received clearance to conduct clinical trials for TLC599 in Taiwan

2014

Collaboration with Ablynx N.V.
Established subsidiaries in Hong Kong, Shanghai, and Melbourne

2013

Collaboration with SciClone, Sandoz, SamchunDang Pharm Co., Ltd. and Yung Shin Pharmaceuticals on various assets
Winner of Potential Star Award in Taipei Biotech Awards
Drug approval and launch for Ampholipad® in Taiwan

2012

Collaboration with Teva Pharmaceuticals
Publicly listed on the Taipei Exchange (TPEx) on Dec 12

2011

Listed on Emerging Market in Taiwan Stock Exchange (ticker: 4152)

2010

Winner of the 6th Taiwan Nano Achievers Award
Established TLC Biopharmaceuticals B.V. in Leiden Science Park, The Netherlands

2009

Winner in the Innovations in Product/System category of Industrial Innovation Achievement Awards
Received Research and Development Innovation Gold Award from Taipei City Government
Received Gold Award from Taiwan’s Ministry of Economic Affairs for TLC178

2008

NanoVNB enters Phase II clinical trial for colorectal cancer

2007

Awarded Red Herring Asia Top 100 Company
Received Technology Commercialization Gold Award from Taipei City Government
Set up preclinical PK and toxicity labs in the Incubation Center of Genomics Research Center at Academia Sinica

2006

Phase 2 clinical trial for NanoVNB
Received Research and Development Innovation Silver Award from Taipei City Government

2005

Founder & Chairman Dr. Keelung Hong awarded Advanced Skill Innovation Award in the Industrial Technology Advancement Awards by Taiwan’s Ministry of Economic Affairs
Received Research and Development Innovation Gold Award from Taipei City Government
Established TLC Biopharmaceuticals and lab in the US

2004

Received Technology Transfer Gold Award from Taipei City Government
Scale-up and Phase I clinical trial for NanoVNB

2003

Setup scale-up production in GMP plant
Expanded operation and relocation to Nangang Software Park

2002

Received Rising Star Award from Taiwan’s Ministry of Economic Affairs
Lipo-Dox approved for ovarian cancer

1997-2001

Conducted preclinical animal experiments and trials for Lipo-Dox

1997

TLC founded with seed-round of financing

goldennet

About Us

Cookies